News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ilypsa, Inc. Completes Phase 1 Clinical Trial Of ILY101 For Hyperphosphatemia Associated With Chronic Kidney Disease


4/20/2006 12:01:48 PM

SANTA CLARA, Calif.--(BUSINESS WIRE)--April 20, 2006--Ilypsa, Inc., pioneering next-generation non-absorbed polymeric drugs for renal and metabolic disorders, today announced it has completed a Phase 1 clinical trial for ILY101, a novel phosphate binding agent that is being developed for the treatment of hyperphosphatemia, a serious complication in patients with chronic kidney disease (CKD) on dialysis.

Read at press release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES